The stock has a 36-month beta value of 1.05. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BIVI is 5.48M, and at present, short sellers hold a 3.43% of that float. On October 25, 2024, the average trading volume of BIVI was 4.55M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BIVI) stock’s latest price update
The stock price of BioVie Inc (NASDAQ: BIVI) has surged by 3.11 when compared to previous closing price of 2.71, but the company has seen a 18.90% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-24 that CARSON CITY, Nev., Oct. 24, 2024 (GLOBE NEWSWIRE) — BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 2,667,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.25 per share.
BIVI’s Market Performance
BioVie Inc (BIVI) has experienced a 18.90% rise in stock performance for the past week, with a 151.73% rise in the past month, and a -31.87% drop in the past quarter. The volatility ratio for the week is 100.91%, and the volatility levels for the past 30 days are at 29.20% for BIVI. The simple moving average for the last 20 days is 70.05% for BIVI stock, with a simple moving average of -47.86% for the last 200 days.
Analysts’ Opinion of BIVI
Many brokerage firms have already submitted their reports for BIVI stocks, with Cantor Fitzgerald repeating the rating for BIVI by listing it as a “Overweight.” The predicted price for BIVI in the upcoming period, according to Cantor Fitzgerald is $7 based on the research report published on July 22, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see BIVI reach a price target of $47. The rating they have provided for BIVI stocks is “Buy” according to the report published on January 15th, 2021.
BIVI Trading at 21.99% from the 50-Day Moving Average
After a stumble in the market that brought BIVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.20% of loss for the given period.
Volatility was left at 29.20%, however, over the last 30 days, the volatility rate increased by 100.91%, as shares surge +127.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.19% upper at present.
During the last 5 trading sessions, BIVI rose by +16.17%, which changed the moving average for the period of 200-days by -78.33% in comparison to the 20-day moving average, which settled at $1.64. In addition, BioVie Inc saw -77.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIVI starting from GORLIN STEVE, who sale 75,680 shares at the price of $1.69 back on Dec 01 ’23. After this action, GORLIN STEVE now owns 46,358 shares of BioVie Inc, valued at $127,899 using the latest closing price.
DO CUONG V, the President & CEO of BioVie Inc, purchase 10,000 shares at $1.78 during a trade that took place back on Nov 30 ’23, which means that DO CUONG V is holding 68,759 shares at $17,800 based on the most recent closing price.
Stock Fundamentals for BIVI
The total capital return value is set at -2.03. Equity return is now at value -208.26, with -106.51 for asset returns.
Based on BioVie Inc (BIVI), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -4.57. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is -11.12.
Currently, EBITDA for the company is -31.95 million with net debt to EBITDA at 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.57.
Conclusion
To sum up, BioVie Inc (BIVI) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
